牛磺酸 Taurine × 第二型糖尿病
結論：證據支持但有警示
兩篇 Meta-analysis 呈現矛盾結果：2022 MA（n=209，5 RCTs）HbA1c 顯著下降（SMD -0.
B 🟡 B 初步證據 附警語發布 ✨ low — community discussion mostly non-commercial
兩篇 Meta-analysis 呈現矛盾結果：2022 MA（n=209，5 RCTs）HbA1c 顯著下降（SMD -0.41，p=0.01），但 2024 MA（n=1024，25 RCTs）HbA1c 未達顯著（WMD -0.341%，p=0.070）；HOMA-IR 與空腹血糖改善較一致，但均為短期（8週）代理指標，缺乏長期臨床終點數據。
現有 RCT 樣本偏小（n=45–120），研究族群集中於伊朗糖尿病患者，外部效度有限。
ADA 2025/2026 標準療程（Rec. 5.16）明確不建議以膳食補充劑改善血糖控制，EFSA 亦拒絕所有牛磺酸健康聲稱，整體監管立場不支持糖尿病應用。
綜合以上，本層獨立評為 C 級（初步訊號但一致性不足，不可作為獨立療法依據）。
⚖️
評分透明度
所有分數由 7 層證據引擎計算，過程公開可查原始分數 0.60
D
C
B
A
S
← 反證據 / 無效有效 / 強證據 →
最終評級
B · 附警語發布
信心度
70%
證據方向大致一致
證據層級
E2
多篇高品質統合分析（≥2 篇一致）
▸查看完整決策路徑（audit trail）
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.603
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 高品質 SR/MA 顯示 positive (2 篇 > 0 negative)
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
The effects of taurine supplementation on diabetes mellitus in humans: A systematic review and meta-analysis
結論：Taurine significantly reduced HbA1c (SMD -0.41, p=0.01), FBS (SMD -1.28, p=0.03), and HOMA-IR (SMD -0.64, p=0.03) across 5 RCTs in diabetic patients.
前往 PubMed
Taurine reduces the risk for metabolic syndrome: a systematic review and meta-analysis of randomized controlled trials
結論：Taurine significantly reduced fasting blood glucose (WMD -5.882 mg/dL, p=0.018) and HOMA index (WMD -0.693, p=0.002); HbA1c reduction did not reach significance (WMD -0.341%, p=0.070).
前往 PubMed
The effects of taurine supplementation on glycemic control and serum lipid profile in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial
結論：FBS (p=0.01), insulin (p=0.01), HOMA-IR (p=0.003), TC (p=0.013) and LDL-C (p=0.041) significantly decreased vs placebo; HbA1c showed no significant change.
前往 PubMed
The Effects of Taurine Supplementation on Metabolic Profiles, Pentosidine, Soluble Receptor of Advanced Glycation End Products and Methylglyoxal in Adults With Type 2 Diabetes
結論：Taurine significantly reduced FBS (p=0.01), HbA1c (p=0.04), insulin (p=0.03), HOMA-IR (p=0.004), pentosidine (p=0.004), and methylglyoxal (p=0.006) vs placebo.
前往 PubMed
Protective and therapeutic effectiveness of taurine supplementation plus low calorie diet on metabolic parameters and endothelial markers in patients with diabetes mellitus: a randomized, clinical …
結論：Taurine significantly reduced insulin and HOMA-IR, and improved oxidative stress and endothelial markers vs placebo; HbA1c and FBG did not show significant improvement.
前往 PubMed
L4a US FDA
支持
FDA has no questions 來源↗
L4b EU EFSA
謹慎
L4c UK NHS
未表態
— 本適應症無對應資料
L4d TW TFDA / 衛福部
中性
本品可於各類食品中視實際需要適量使用，限於補充食品中不足該營養素時使用。 來源↗
L4e WHO
未表態
JECFA (Meeting 69, 2008): 'No safety concern at current levels of intake when used as a flavouring agent.' Codex Alimentarius (CXS 72-1981): taurine is an optional (not mandatory) ingredient in infant formula; mandatory addition is not considered necessary. 來源↗
L5a NIH Office of Dietary Supplements
謹慎
L5b Mayo Clinic
未表態
— 本適應症無對應資料
L5c Cleveland Clinic
中性
L5d Harvard Health
未表態
— 本適應症無對應資料
L5e Specialty Society (condition-mapped)
謹慎
PTT · Dcard · Mobile01 彙整自公開論壇討論，非統計抽樣，僅反映社群風向。
廣告 / 業配密度 低度
低中高
📍立場總覽
PTT FITNESS/regimen 的二型糖尿病討論幾乎都聚焦在減醣、運動、胰島素阻抗，牛磺酸僅以能量飲料成分被順帶提及，無人分享以牛磺酸控糖的實測經驗；痞客邦/部落格僅見轉貼式衛教文，Dcard/Mobile01 無相關討論。台灣社群對「牛磺酸用於糖尿病」幾乎沒有真實使用討論。
💬社群實感
無共識（台灣社群無以牛磺酸控糖的實測討論）
- 醫療營養治療與減重
- 規律身體活動
- Metformin（二甲雙胍）
查看 ClaimReview 結構化資料 (JSON-LD)
{
"@context": "https://schema.org",
"@type": "ClaimReview",
"url": "https://gpt-dict.com/claim/CLM-COND-type2-diabetes-INT-taurine-001/",
"datePublished": "2026-06-01",
"author": {
"@type": "Organization",
"name": "gpt-dict.com",
"url": "https://gpt-dict.com"
},
"claimReviewed": "牛磺酸能改善第二型糖尿病",
"inLanguage": "zh-TW",
"itemReviewed": {
"@type": "Claim",
"appearance": []
},
"reviewRating": {
"@type": "Rating",
"ratingValue": 3,
"bestRating": 5,
"worstRating": 1,
"alternateName": "🟡 B 初步證據"
}
}